Purchase this article with an account.
Lindsay Davis, Kundandeep Nagi, Dip Jadav; Prostaglandin Efficacy in the Hispanic Population. Invest. Ophthalmol. Vis. Sci. 2013;54(15):760. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the intraocular pressure (IOP) reduction with Latanoprost 0.005% in the Hispanic and Caucasian population.
A retrospective review of 212 subjects was performed. Of these, the prostaglandin (PGA) mediated IOP reduction of 122 Hispanic eyes was compared to 90 Caucasian eyes. In addition, we further examined the medication’s effect based on age, gender and phakic status. Main outcome measures included average and percent IOP reduction as a surrogate for efficacy, calculated by comparing the pre-treatment IOP to the IOP taken after six weeks of monotherapy with Latanoprost. Data was summarized and compared using Wilcoxon 2-sample test. A p-value <0.05 was considered as statistically significant.
Of the 183 eyes that responded to PGA monotherapy, no statistically significant difference was found between ethnic groups (p=0.6). The IOP decreased by 8.02 mm Hg (29.9%, n=103) in Hispanic eyes and by 7.96 (29.6%, n=80) in Caucasian eyes. When comparing Hispanic and Caucasian males and females, no statistically significant difference was found (8.03 vs 8.02 mm Hg in males, p>0.05 and 8.00 vs 7.89 mm Hg in females, p>0.05 respectively). Further analysis comparing specific age groups and lens status between Caucasian and Hispanic eyes yielded no statistically significant difference in IOP lowering.
To our knowledge, no prior study has compared IOP reduction with prostaglandin analogs in the Hispanic and Caucasian population. This study shows equivalent efficacy among Hispanic and Caucasian patients using nightly latanoprost.
This PDF is available to Subscribers Only